What Is End-of-Life Care Like for Advanced Adrenocortical Carcinoma (ACC)?
By CRYSTAL BAI •
The short answer: Adrenocortical carcinoma (ACC) is a rare, aggressive adrenal cancer with high recurrence rates. In advanced stages, palliative care manages hormonal excess syndromes (Cushing's, virilization), pain from metastases, and the psychological burden of a rare cancer with limited treatment options. Early palliative care integration improves quality of life significantly.
Understanding Advanced Adrenocortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare malignancy arising from the cortex of the adrenal gland, with approximately 1-2 cases per million per year. It is frequently functional — producing excess cortisol, androgens, or aldosterone — creating distinctive hormonal symptoms in addition to tumor mass effects.
ACC has high recurrence rates even after complete resection, and metastatic disease responds poorly to available treatments (mitotane, EDP-M chemotherapy). Prognosis in advanced ACC is typically measured in months to 1-2 years.
Key Symptom Challenges in Advanced ACC
ACC creates both hormonal and mass-related symptoms:
- Cushing's syndrome from cortisol excess: Weight gain (especially central), hypertension, diabetes, skin fragility, immune suppression, osteoporosis, profound muscle weakness, psychiatric symptoms (depression, psychosis)
- Virilization from androgen excess: In women — hirsutism, acne, voice changes, clitoral enlargement; in men — rarely symptomatic
- Mitotane toxicity: First-line treatment mitotane causes significant GI toxicity, neurological symptoms, and adrenal insufficiency requiring steroid replacement
- Mass symptoms: Abdominal pain, hepatic pain from metastases, lung symptoms from pulmonary spread
- Adrenal insufficiency: Both the disease and its treatment can cause adrenal insufficiency requiring careful steroid management at end of life
Palliative Care Priorities
- Hormonal symptom management: Controlling cortisol excess improves quality of life dramatically; steroidogenesis inhibitors (ketoconazole, metyrapone) may be used palliatively
- Adrenal insufficiency management: Patients who have received mitotane or bilateral adrenalectomy need careful steroid coverage, especially at end of life when oral medications may not be absorbed
- Pain management: Multi-modal analgesia for abdominal and metastatic pain
- Psychiatric support: Cortisol excess causes depression and cognitive changes; psychiatric consultation is often needed
- Nutritional support: Managing Cushing's-related diabetes, fluid retention, and nutritional decline
ACC-Specific End-of-Life Considerations
Several ACC-specific issues require advance planning: steroid stress dosing protocols for home emergencies, deciding when to discontinue mitotane (significant toxicity vs. potential benefit), and managing the complex endocrine environment of dying. These require coordination between oncology, endocrinology, and palliative care. The ACC International Network (accinternet.org) provides ACC patient community support.
Frequently Asked Questions
What is the prognosis for metastatic adrenocortical carcinoma?
Metastatic ACC has a poor prognosis, with median overall survival of approximately 12-18 months in most series. Some patients with indolent metastatic disease and good performance status achieve longer survival. Prognosis is better for non-functional tumors and those with limited metastatic burden. Individual prognosis should be discussed directly with an ACC specialist.
What is Cushing's syndrome and how is it managed in ACC?
Cushing's syndrome results from ACC producing excess cortisol, causing weight gain, hypertension, diabetes, skin thinning, muscle weakness, and psychiatric symptoms. It is managed palliatively with steroidogenesis inhibitors (ketoconazole, metyrapone, osilodrostat) that block cortisol production. Controlling Cushing's can significantly improve quality of life even in advanced disease.
What is mitotane and when should it be stopped?
Mitotane (Lysodren) is the main systemic therapy for ACC, with direct adrenal toxicity as its mechanism. It causes significant GI, neurological, and endocrine side effects and requires adrenal replacement therapy. The decision to stop mitotane — weighing disease control against toxicity and quality of life — is a key goals-of-care decision in advanced ACC, ideally made in advance with palliative care input.
Does ACC require special hospice considerations?
Yes. Patients with ACC on hospice have unique needs: steroid supplementation must be continued to prevent life-threatening adrenal crisis; hormonal symptom management may need to continue for comfort; medication routes may need to change as oral intake declines. Briefing the hospice team on ACC-specific endocrine needs is essential.
Where can I find ACC specialists?
ACC is rare enough that specialist care is concentrated at major academic centers. Leading ACC programs in the US include the University of Michigan (National ACC Registry), MD Anderson, and Ohio State University. Internationally, the ENSAT (European Network for the Study of Adrenal Tumors) provides resources. The ACC International Network (accinternet.org) connects patients with specialists and clinical trials.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.